GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » 5-Year Dividend Growth Rate

REVB (Revelation Biosciences) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences 5-Year Dividend Growth Rate?

Revelation Biosciences's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Revelation Biosciences's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Revelation Biosciences's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Revelation Biosciences's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Revelation Biosciences's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's 5-Year Dividend Growth Rate falls into.


;
;

Revelation Biosciences 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Revelation Biosciences  (NAS:REVB) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Revelation Biosciences's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2024 )/ EPS without NRI (Q: Dec. 2024 )
=0/ -4.985
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » 5-Year Dividend Growth Rate
Comparable Companies
QRON KANT QLGN ZVSA THAR ADTX OMGAQ PBM VCNX SCNI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Website
https://www.revbiosciences.com
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Executives
George F Tidmarsh director, 10 percent owner
Lakhmir S Chawla director 1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l other: Former 10% owner 2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif other: Former 10% Owner 2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a. other: Former 10% owner 6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris other: Former 10% owner 6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd other: Former 10% owner 22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa other: Former 10% owner 25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke director, officer: Chief Executive Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver director 725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii officer: Chief Financial Officer 3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis 10 percent owner 190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc 10 percent owner 20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606